Analysts see the market near $100 billion a year within a decade. Lilly says retatrutide cut weight by more than 28% over 18 months in a key trial.
Recap by typeshit. Full story at KSL.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
Moneycontrol says the Indian drugmaker is focusing on specialised production of peptides and antibody-drug conjugates rather than crowded weight loss drugs.
Piramal plans to put $100 million into niche manufacturing this year while rivals pile into GLP-1, and says it won't go back to drug discovery.
Loading…